|
1
|
Younossi ZM, Loomba R, Rinella ME,
Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro
F, Caldwell SH, Ratziu V, et al: Current and future therapeutic
regimens for nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis. Hepatology. 68:361–371. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Younossi Z, Tacke F, Arrese M, Chander
Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George
J, Fan J and Vos MB: Global perspectives on nonalcoholic fatty
liver disease and nonalcoholic steatohepatitis. Hepatology.
69:2672–2682. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Yabiku K, Mutoh A, Miyagi K and Takasu N:
Effects of oral antidiabetic drugs on changes in the
liver-to-spleen ratio on computed tomography and inflammatory
biomarkers in patients with type 2 diabetes and nonalcoholic fatty
liver disease. Clin Ther. 39:558–566. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dong Y, Lv Q, Li S, Wu Y, Li L, Li J,
Zhang F, Sun X and Tong N: Efficacy and safety of glucagon-like
peptide-1 receptor agonists in non-alcoholic fatty liver disease: A
systematic review and meta-analysis. Clin Res Hepatol
Gastroenterol. 41:284–295. 2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Newsome PN, Buchholtz K, Cusi K, Linder M,
Okanoue T, Ratziu V, Sanyal AJ, Sejling AS and Harrison SA:
NN9931-4296 Investigators. A placebo-controlled trial of
subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J
Med. 384:1113–1124. 2021.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Raj H, Durgia H, Palui R, Kamalanathan S,
Selvarajan S, Kar SS and Sahoo J: SGLT-2 inhibitors in
non-alcoholic fatty liver disease patients with type 2 diabetes
mellitus: A systematic review. World J Diabetes. 10:114–132.
2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ferrannini E, Ramos SJ, Salsali A, Tang W
and List JF: Dapagliflozin monotherapy in type 2 diabetic patients
with inadequate glycemic control by diet and exercise: A
randomized, double-blind, placebo-controlled, phase 3 trial.
Diabetes Care. 33:2217–2224. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dhillon S: Dapagliflozin: A review in type
2 diabetes. Drugs. 79:1135–1146. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bays HE, Sartipy P, Xu J, Sjöström CD and
Underberg JA: Dapagliflozin in patients with type II diabetes
mellitus, with and without elevated triglyceride and reduced
high-density lipoprotein cholesterol levels. J Clin Lipidol.
11:450–458.e1. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Suijk DLS, van Baar MJB, van Bommel EJM,
Iqbal Z, Krebber MM, Vallon V, Touw D, Hoorn EJ, Nieuwdorp M,
Kramer MMH, et al: SGLT2 inhibition and uric acid excretion in
patients with type 2 diabetes and normal kidney function. Clin J Am
Soc Nephrol. 17:663–671. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jaikumkao K, Pongchaidecha A, Chueakula N,
Thongnak LO, Wanchai K, Chatsudthipong V, Chattipakorn N and
Lungkaphin A: Dapagliflozin, a sodium-glucose co-transporter-2
inhibitor, slows the progression of renal complications through the
suppression of renal inflammation, endoplasmic reticulum stress and
apoptosis in prediabetic rats. Diabetes Obes Metab. 20:2617–2626.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wiviott SD, Raz I, Bonaca MP, Mosenzon O,
Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, et
al: Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N
Engl J Med. 380:347–357. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
American Diabetes Association Professional
Practice Committee. 2. Classification and diagnosis of diabetes:
standards of medical care in diabetes-2022. Diabetes Care. 45
(Suppl 1):S17–S38. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
European Association for the Study of the
Liver (EASL); European Association for the Study of Diabetes
(EASD); European Association for the Study of Obesity (EASO).
EASL-EASD-EASO clinical practice guidelines for the management of
non-alcoholic fatty liver disease. J Hepatol. 64:1388–1402.
2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Rinella ME: Nonalcoholic fatty liver
disease: A systematic review. JAMA. 313:2263–2273. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Eriksson JW, Lundkvist P, Jansson PA,
Johansson L, Kvarnström M, Moris L, Miliotis T, Forsberg GB,
Risérus U, Lind L and Oscarsson J: Effects of dapagliflozin and n-3
carboxylic acids on non-alcoholic fatty liver disease in people
with type 2 diabetes: A double-blind randomised placebo-controlled
study. Diabetologia. 61:1923–1934. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Latva-Rasku A, Honka MJ, Kullberg J,
Mononen N, Lehtimäki T, Saltevo J, Kirjavainen AK, Saunavaara V,
Iozzo P, Johansson L, et al: The SGLT2 inhibitor dapagliflozin
reduces liver fat but does not affect tissue insulin sensitivity: A
randomized, double-blind, placebo-controlled study with 8-week
treatment in type 2 diabetes patients. Diabetes Care. 42:931–937.
2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Choi DH, Jung CH, Mok JO, Kim CH, Kang SK
and Kim BY: Effect of dapagliflozin on alanine aminotransferase
improvement in type 2 diabetes mellitus with non-alcoholic fatty
liver disease. Endocrinol Metab (Seoul). 33:387–394.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Arase Y, Shiraishi K, Anzai K, Sato H,
Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T and
Kagawa T: Effect of sodium glucose co-transporter 2 inhibitors on
liver fat mass and body composition in patients with nonalcoholic
fatty liver disease and type 2 diabetes mellitus. Clin Drug
Investig. 39:631–641. 2019.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Phrueksotsai S, Pinyopornpanish K,
Euathrongchit J, Leerapun A, Phrommintikul A, Buranapin S,
Chattipakorn N and Thongsawat S: The effects of dapagliflozin on
hepatic and visceral fat in type 2 diabetes patients with
non-alcoholic fatty liver disease. J Gastroenterol Hepatol.
36:2952–2959. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kinoshita T, Shimoda M, Nakashima K,
Fushimi Y, Hirata Y, Tanabe A, Tatsumi F, Hirukawa H, Sanada J,
Kohara K, et al: Comparison of the effects of three kinds of
glucose-lowering drugs on non-alcoholic fatty liver disease in
patients with type 2 diabetes: A randomized, open-label, three-arm,
active control study. J Diabetes Investig. 11:1612–1622.
2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kuchay MS, Krishan S, Mishra SK, Farooqui
KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, et
al: Effect of empagliflozin on liver fat in patients with type 2
diabetes and nonalcoholic fatty liver disease: A randomized
controlled trial (E-lift trial). Diabetes Care. 41:1801–1808.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kahl S, Gancheva S, Straßburger K, Herder
C, Machann J, Katsuyama H, Kabisch S, Henkel E, Kopf S, Lagerpusch
M, et al: Empagliflozin effectively lowers liver fat content in
well-controlled type 2 diabetes: A randomized, double-blind, phase
4, placebo-controlled trial. Diabetes Care. 43:298–305.
2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Inoue M, Hayashi A, Taguchi T, Arai R,
Sasaki S, Takano K, Inoue Y and Shichiri M: Effects of
canagliflozin on body composition and hepatic fat content in type 2
diabetes patients with non-alcoholic fatty liver disease. J
Diabetes Investig. 10:1004–1011. 2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sumida Y, Murotani K, Saito M, Tamasawa A,
Osonoi Y, Yoneda M and Osonoi T: Effect of luseogliflozin on
hepatic fat content in type 2 diabetes patients with non-alcoholic
fatty liver disease: A prospective, single-arm trial (LEAD trial).
Hepatol Res. 49:64–71. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ito D, Shimizu S, Inoue K, Saito D,
Yanagisawa M, Inukai K, Akiyama Y, Morimoto Y, Noda M and Shimada
A: Comparison of ipragliflozin and pioglitazone effects on
nonalcoholic fatty liver disease in patients with type 2 diabetes:
A randomized, 24-week, open-label, active-controlled trial.
Diabetes Care. 40:1364–1372. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Swe MT, Thongnak L, Jaikumkao K,
Pongchaidecha A, Chatsudthipong V and Lungkaphin A: Dapagliflozin
not only improves hepatic injury and pancreatic endoplasmic
reticulum stress, but also induces hepatic gluconeogenic enzymes
expression in obese rats. Clin Sci (Lond). 133:2415–2430.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Li L, Li Q, Huang W, Han Y, Tan H, An M,
Xiang Q, Zhou R, Yang L and Cheng Y: Dapagliflozin alleviates
hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway.
Front Pharmacol. 12(589273)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Shaaban HH, Alzaim I, El-Mallah A, Aly RG,
El-Yazbi AF and Wahid A: Metformin, pioglitazone, dapagliflozin and
their combinations ameliorate manifestations associated with NAFLD
in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and
anti-apoptotic mechanisms. Life Sci. 308(120956)2022.PubMed/NCBI View Article : Google Scholar
|
|
30
|
ElMahdy MK, Helal MG and Ebrahim TM:
Potential anti-inflammatory effect of dapagliflozin in HCHF
diet-induced fatty liver degeneration through inhibition of TNF-α,
IL-1β, and IL-18 in rat liver. Int Immunopharmacol.
86(106730)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bellanti F, Lo Buglio A, Dobrakowski M,
Kasperczyk A, Kasperczyk S, Aich P, Singh SP, Serviddio G and
Vendemiale G: Impact of sodium glucose cotransporter-2 inhibitors
on liver steatosis/fibrosis/inflammation and redox balance in
non-alcoholic fatty liver disease. World J Gastroenterol.
28:3243–3257. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Garvey WT, Van Gaal L, Leiter LA,
Vijapurkar U, List J, Cuddihy R, Ren J and Davies MJ: Effects of
canagliflozin versus glimepiride on adipokines and inflammatory
biomarkers in type 2 diabetes. Metabolism. 85:32–37.
2018.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Hashimoto K and Akagi M: The role of
oxidation of low-density lipids in pathogenesis of osteoarthritis:
A narrative review. J Int Med Res.
48(300060520931609)2020.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Minciuna I, Gallage S, Heikenwalder M,
Zelber-Sagi S and Dufour JF: Intermittent fasting-the future
treatment in NASH patients? Hepatology. 78:1290–1305.
2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Shimizu M, Suzuki K, Kato K, Jojima T,
Iijima T, Murohisa T, Iijima M, Takekawa H, Usui I, Hiraishi H and
Aso Y: Evaluation of the effects of dapagliflozin, a sodium-glucose
co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using
transient elastography in patients with type 2 diabetes and
non-alcoholic fatty liver disease. Diabetes Obes Metab. 21:285–292.
2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Akuta N, Kawamura Y, Watanabe C, Nishimura
A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, et
al: Impact of sodium glucose cotransporter 2 inhibitor on
histological features and glucose metabolism of non-alcoholic fatty
liver disease complicated by diabetes mellitus. Hepatol Res.
49:531–539. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
He K, Li J, Xi W, Ge J, Sun J and Jing Z:
Dapagliflozin for nonalcoholic fatty liver disease: A systematic
review and meta-analysis. Diabetes Res Clin Pract.
185(109791)2022.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tosaki T, Kamiya H, Himeno T, Kato Y,
Kondo M, Toyota K, Nishida T, Shiroma M, Tsubonaka K, Asai H, et
al: Sodium-glucose co-transporter 2 inhibitors reduce the abdominal
visceral fat area and may influence the renal function in patients
with type 2 diabetes. Intern Med. 56:597–604. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Sertbas M, Sertbas Y, Okuroglu N, Akyildiz
AB, Sancak S and Ozdemir A: Effıcacy and safety of dapagliflozin on
diabetic patients receiving high-doses of insulin. Pak J Med Sci.
35:399–403. 2019.PubMed/NCBI View Article : Google Scholar
|
